Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $189,893.45 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 25,085 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $7.57, for a total transaction of $189,893.45. Following the completion of the sale, the chief executive officer now directly owns 831,833 shares of the company’s stock, valued at approximately $6,296,975.81. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Wednesday, August 7th, Zhenya Lindgardt sold 12,327 shares of Sera Prognostics stock. The stock was sold at an average price of $7.42, for a total transaction of $91,466.34.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA traded up $0.10 during mid-day trading on Tuesday, reaching $7.40. 60,062 shares of the company were exchanged, compared to its average volume of 195,324. The firm has a market cap of $246.94 million, a price-to-earnings ratio of -6.83 and a beta of 1.03. The firm’s 50-day simple moving average is $7.14 and its 200 day simple moving average is $8.31. Sera Prognostics, Inc. has a 1 year low of $1.56 and a 1 year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.08 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 11,843.79%. During the same period in the previous year, the business posted ($0.34) EPS. On average, research analysts forecast that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. purchased a new position in shares of Sera Prognostics during the 1st quarter worth approximately $18,420,000. AWM Investment Company Inc. lifted its holdings in Sera Prognostics by 56.0% during the 1st quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock worth $5,320,000 after buying an additional 209,762 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares in the last quarter. Ballentine Partners LLC acquired a new stake in Sera Prognostics during the 2nd quarter worth approximately $294,000. Finally, Twelve Points Wealth Management LLC acquired a new stake in Sera Prognostics during the 2nd quarter worth approximately $257,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.